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Abstract
The general scope of a project to determine the protein molecules that comprise the cells within
the human body is framed. By focusing on protein primary structure as expressed in specific cell
types, this concept for a cell-based version of the Human Proteome Project (CB-HPP) is crafted
in a manner analogous to the Human Genome Project while recognizing that cells provide a
primary context in which to define a proteome. Several activities flow from this articulation of the
HPP, which enables the definition of clear milestones and deliverables. The CB-HPP highlights
major gaps in our knowledge regarding cell heterogeneity and protein isoforms, and calls for
development of technology that is capable of defining all human cell types and their proteomes.
The main activities will involve mapping and sorting cell types combined with the application of
beyond the state-of-the art in protein mass spectrometry.
Key words: Human proteome project, Cell type, Top down proteomics, Protein isoforms, Mass
spectrometry, Human genome project
Introduction
One goal of the Human Proteome Project is to define theprotein molecules that make up the human body. Such
an activity could generate a reference list to better
understand and detect human disease, and, with hyperfine
detail, our responses to new therapeutics. What follows is a
short synopsis of an idea to crystallize the Human Proteome
Project (HPP) into a focused effort to map the natural
structure and variation of human beings at the molecular
level, much like the Human Genome Project completed a
decade ago.
Whereas the decoding of the human genome involved the
determination of a linear sequence of A’s, G’s, C’s, and T’s
present in most of our cells, proteins are far more context-
dependent. This fact, along with the complexity of highly
processed protein molecules and the lack of amplification
methods, forces one to define the context and scope of a
compelling project that builds on the exploding knowledge
of human genomes. This includes describing a clear
endpoint of high value that will transform both basic and
clinical research, and accelerate the delivery of societal
promises made for the post-genomic practice of medicine.
Discussion
Current Strategies for the HPP
Launched a decade ago [1], the Human Proteome Organi-
zation, or HUPO (http://www.hupo.org/), has focused on
creating knowledge bases, antibody-based reagents, and
mass spectrometry-based proteomics using a “Bottom Up”
analytical strategy. Using antibodies, the construction of a
Human Protein Atlas (http://www.proteinatlas.org/) has
yielded immunofluorescence images profiling protein ex-
pression from ~40 % of human genes. There have been two
articulations of initiatives using protein mass spectrometry
thus far. A “biology/disease” approach, generally linked to
disease research, was first to be put forth (e.g., for the human
plasma proteome, the liver, the brain, etc.) [2, 3]. This has
come to be known also as a “protein-centric” or discovery
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approach [4]. More recently, a “gene-centric” (aka, a
“chromosome-centric”, or C-HPP) approach has emerged
[5, 6], with groups in many countries coordinating national
efforts to map the abundance, distribution, and sub-cellular
localization of proteins whose genes are co-located on the
same chromosome. One additional achievement of HUPO
has been to begin unifying the field of proteomics via the
Proteomics Standards Initiative [7] and to provide a forum
for coordinated efforts to improve cross-lab reproducibility
[8]. For ease, Table 1 summarizes the current articulations of
the HPP.
A new context in which to place the HPP takes
inspiration from a particular level of the natural organization
present in the human body (Figure 1), with cell type
assuming the primary, defining context for the project. With
a few exceptions, it is individual cells that convert the
genome into the proteome, thereby defining cell type
through biomolecule expression. A cell-centric focus places
a premium on knowing and classifying all the sub-types of
cells in the human body. With relevance across the spectrum
of human disease, a cell mapping stage naturally precedes
the large-scale characterization of protein molecules (vide
infra). This is akin to the genome mapping stages (first using
genetic and then physical techniques) that dominated the
first decade of the HGP (Table 2, row 2). Stimulated by the
end goal and the resources to achieve it, DNA sequencing
technologies underwent development at a sharply accelerat-
ed rate during this mapping stage of the project. A similar
stage of technology development for quantitative measure-
ment of protein forms is envisioned for this “Cell-Based”
articulation of the HPP (or “CB-HPP”; Table 1).
Mapping Cell Types
It is clear that cellular heterogeneity is a major point of
confusion in normal and disease biology, and that the
textbook number of ~230 different cell types in the
human body is out of date in the age of molecular
medicine. The cell mapping stage of the CB-HPP can
utilize a variety of cell surface markers for fluorescence
assisted cell sorting (FACS) to prepare 1000 to
1,000,000 cells of high purity prior to cell-specific
proteomics [9]. Further, a cell-based project calls for
the large-scale discovery and validation of cell surface
markers, using capture technologies for cell surface
proteins [10], FACS, mass cytometry [11], RNA-seq,
and other multi-parameter tools to categorize the cell
types present in the human body. The Cellpedia project
has generated an ontology of cell types raising the
classical number of 230 to 92500 currently [12]. Given
that we will add substantially to the number of cell and
sample types during the cell mapping stage of the
project, the number could rise to perhaps ~4000 cell
types. Defining the variation of healthy cells using
quantitative and isoform-resolved proteomics, both within
an individual and within populations, would provide a
rich basis for subsequent disease-driven research and
regenerative medicine. The source of cells should be
highly restricted to those isolated from primary tissue.
The CB-HPP has a high bar for sampling prior to mass
spectrometry-based proteomics, a will use classifiers for
definition of primary cell type.
Defining the Proteome of Specific Cell Types
This cell-based articulation of the Human Proteome Project
takes inspiration, where appropriate, from the experience of the
Human Genome Project (Table 2). The most analogous effort
to the genome project is to provide the definitive primary
structure for Homo sapiens at the level of protein molecules.
This focused effort would involve the definition of all
detectable proteoforms1 of carefully defined and sorted cell
types from the human body. Assuming there are ~250,000
distinct proteoforms detectable in a given cell type by
technologies ready within a 10-year time horizon, the whole
cell-based project involves characterization of at least 1 billion
proteoforms present in nondiseased cell types (Figure 2).
Combined with the 10 major body fluids such as blood [13]—
the core of the CB-HPP project would involve identification,
characterization, and quantitation of over 1 billion detectable
protein forms. The precise level of analytical depth could be
adjusted once a cost versus depth model is in place prior to a
production scale effort being launched around the time the C-
HPP is projected to be completed in the year ~2022 [5]. To
facilitate interpretation of splicing events, mutations, and
coding polymorphisms, samples would be subjected to parallel
genome sequencing and RNA-seq using NGS.
The Human Genome Project involved taking a grand
inventory of human DNA. Similarly, the proposed CB-HPP
1The term “isoform” is ambiguous, so a new term “proteoform” is used
instead (short for “protein form” or “protein species”). Some prefer a strict
use of the term “isoform” for protein products of related genes, or those
arising from polymorphisms/mutations within protein-coding regions of
genes. The term “proteoform” is used here to describe highly related protein
molecules arising from all combinatorial sources of variation giving rise to
products arising from a single gene. These include the genetic variations just
mentioned, along with alternative splicing of RNA and post-translational
modification.
Table 1. Abbreviations Used to Notate Articulations of the Human
Proteome Project (HPP)







CB-HPP Cell-based Human Proteome
Project
2012
aAlso known as the organ/tissue-based HPP
bAlso known as the gene-centric HPP
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would create definitive knowledge of cell types and the
protein molecules within them. With a simplified focus on
cell type and protein primary structure, the core of a focused
project based on mass spectrometry can then be crafted:
 Goal: By the year 2030, to develop and apply the
technology to analyze the ~1 billion primary structures
of protein forms present in all the cell types and major
fluids present in the human body.
This primary goal of the CB-HPP will drive development
of technologies to transform the proteome from a nebulous
enigma into a closed system—with knowable molecules and
intelligible codes. One promising approach is the “Top Down”
Figure 1. The levels of organization in the human body. The cell-based approach to the Human Proteome Project (CB-HPP)
recognizes cell type as a primary context for mass spectrometry-based protein analysis to measure the molecular complexity
present in the body naturally. The CB-HPP also calls for accelerated development of new and emerging technologies to better
define cell types and precisely catalogue whole protein molecules
Table 2. Comparison of the Human Genome Project (HGP) and the Cell-Based Version of the Human Proteome Project (CB-HPP)
Aspect of Project Human Genome Project CB-Human Proteome Project
1 Context of cell type? No Yes
2 Mapping phase Required? Yes (Genetic+Physical) Yes (Cell-based)
3 Target size 3.2×109 base pairs ~1×109 protein forms
4 Leap in technology Required? Yes Yes
5 Model systems? Yes (several) Yes (e.g., microorganisms,
S. cerevisiae)
6 Number of donors 5 or 22 people Thousands
7 Time 15 Years ~20 Years
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mass spectrometric strategy for analyzing molecules, now
achievable for thousands of intact proteoforms [14]. For
perspective, almost all practitioners of large-scale proteomics
in discovery and targetedmodes use themethod of “BottomUp”
proteomics, which employs proteases to digest the primary
structures of whole proteins present naturally. Clearly, both
strategies can work together in a project that unifies the gene-
and protein-centric articulations of the HPP. As judged by
comparison with RNA-seq, Bottom Up methods are asymptot-
ically approaching the ability to completely detect all expressed
proteins (~10,000) in discovery mode from a single human cell
type [15, 16]. Detection of proteoforms produced from these
~10,000 genes from carefully defined and isolated cell types
then becomes the primary target for technology development in
mass spectrometry-based proteomics.
This fresh and focused approach to the human proteome
highlights major gaps in our current understanding of
proteins and leads to a call for technological innovations
(like the pioneers of genomics in the late 1980s). What
combinations of coding polymorphisms, alternative splice
forms, and post-translational modifications create the con-
stellation of proteoforms present in each cell type? Once
technologies are in place to answer this, we can address the
question of how they vary in human disease in a determin-
istic and comprehensive fashion. A cell-based Human
Proteome Project places a premium on defining and isolating
specific cell types prior to analysis with 100 % sequence
coverage for proteoforms detected at a copy number of 10
and above. Mainstream technologies in proteomics cover
G20 % of the sequence space of the detectable proteome, and
suffer limitations from the protein inference problem.
An Early Example: Knowing Proteoforms
of Human Histones
The human genome as presented in chromatin is 1/2
DNA and 1/2 protein by weight – and knowledge of
histone forms across the ~60 million nucleosomes in
diploid cells is now in view from application of the full
complement of mass spectrometric methods over the
years. Recently, knowledge of over a thousand distinct
molecular forms of core and linker histones has been
obtained by analysis of intact histones. With this bird’s
eye perspective (i.e., molecular composition and approx-
imate quantity), we have a reasonably good “basis set”
of histone forms that are present down to a copy number
of ~1000. While increased depth of this analysis will
uncover thousands (not billions) more histone proteo-
forms in the future, we can already use this reference set
to better understand combinations of modifications, their
epigenetic contribution to diseases, and our responses to
epigenetic-based therapeutics (e.g., those in development
for a variety of cancers of the blood).
Beyond Primary Structure: Capturing Protein
Pleiotropism at All Levels of Organization
in the Human Body
Proteins are heterogeneous and dynamic molecules in time
and space. This is the reason why they are critical to our
understanding of precise mechanisms in complex diseases.
The dynamic nature of proteins also makes their analysis
more challenging than the genome in several respects. The
context of proteins in large complexes, organelles, lipid
membranes, and organ/tissue type can defocus the protein
analysis picture. However, recent developments do give
hints of how we might proceed. For example, the canonical
Top-Down experiment using mass spectrometry (i.e., com-
plete analysis of protein primary structure) already has a
next-generation counterpart, which includes characterization
of the quaternary structure of megadalton protein complexes
using native electrospray [17]. Also, by linking “Top Down”
and “Bottom Up” flavors of mass spectrometry to separa-
tions that fractionate organelles or protein complexes, their
composition can be built up using the concept of co-
fractionation [18, 19]. Further, cellular and sub-cellular
localization of proteins can be provided by the Human
Protein Atlas, already well underway. In addition to
capturing the tissue and organ context within the body
(initiatives also underway in the HUPO consortium), such
details on organellular localization and protein complexation
form additional goals (added at considerable expense) to
round out a project with the integrated resources to provide
precise molecular information at each level of organization
present in the human body (Figure 1).
Comparing/Contrasting with the Human Genome
Project
Without an analogue to the polymerase chain reaction (PCR)
for proteins, the challenge of the human proteome requires
some different strategies and tactics (Table 2). When the
HGP project was begun the technological hurdles seemed
insurmountable. However, the architects of the HGP
recognized that when conditions are right, methodological
advances come more quickly than expected. The mapping
phase of the human genome provided meaningful linkages
Figure 2. Graphical depiction of the cell-based version of
the Human Proteome Project (CB-HPP)
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to disease research and a “Top Down” scaffold that anchored
the “Bottom Up” method of whole genome shotgun
sequencing. In addition to improving cell-based separations
and mass spectrometric-based analyses of endogenous
proteoforms, the call for disruptive technologies in proteo-
mics would be given new voice. Assuming a cost on the
same scale and growth curve of the Human Genome Project,
one should demonstrate value and performance in pilot
projects. While small bacteria like H. influenzae served
nicely as models to develop whole genome shotgun
sequencing, most bacterial proteins are not highly modified
into a diversity of proteoforms. Despite this, such micro-
organisms would serve as excellent models to judge
completeness and benchmark technologies capable of mea-
suring detectable proteins with complete coverage of their
primary structures (Table 2, row 5). Also, pilot projects on
readily obtained human cell types can commence straight
away (e.g., those of the hematopoietic system). Discovery of
surface markers and methods for defining and sorting
unfixed cells from solid tissue is a critical early part of the
cell-mapping phase for the CB-HPP, where proteoforms are
inventoried on a cell-specific basis.
Regarding the Molecular Variation of DNA
and Proteins
While the genome is quite stable and definable, there is
substantial variation of it through mutation and polymor-
phism in populations. This variation is becoming known
more fully as we reach the era of the $1000 genome [20].
The proteome has greater variation, but does not defy
definition (particularly when each sample could readily have
its full genome determined). Therefore, we can identify
meaningful goals (vide supra), recognizing the differences
between the genome and the more pleotropic proteome.
Another major difference is the sampling of proteins versus
DNA. For proteomics, the demands of ethical sampling
would increase the requirement for a highly collaborative
consortium and would extend the project in time.
Cost and Return
The Human Genome Project involved mapping stages and
much technology development stimulated by articulation
and funding of the project. Even after 2003, continued
stimulus through the National Institutes of Health contribut-
ed to the amazing drop of more than six orders of magnitude
in cost to sequence DNA. This created over 300,000 new
jobs and an estimated~$700 billion of economic activity
[21]. A similar trajectory could be envisioned for the
acquisition of information of the estimated ~1 billion
proteoforms (4000 cell types×250,000 forms/type=1 billion
protein forms). Not until the cost reaches less than $1/
proteoform would a production scale effort be launched.
This would provide a target to stimulate public and
private sector efforts to create disruptive technologies
with orders-of-magnitude increases in efficiency for
discovery- and targeted-proteomics.
Summary
The cell-based version of the Human Proteome Project, or
CB-HPP, relies on two simple tenets. (1) Cells convert the
blueprint of life into proteins. Therefore, a proteome project
should use cell type as its primary index. (2) The “Top
Down” philosophy of molecular analysis can be used in
conjunction with the C-HPP project [5] to determine the
complete primary structures of protein molecules on a cell-
specific basis. Adherence to these tenets sharply focuses a
long-term effort to create a more solid foundation for 21st
century biology and provides clear metrics of progress and
completion.
Outlook
This new approach to the Human Proteome Project calls for
nonincremental technological leaps, and recognizes the
biological hierarchy present naturally in our bodies. The
CB-HPP would provide fundamental knowledge of all cells
and detectable forms of protein molecules in a range of
healthy human bodies. Such knowledge would revolutionize
our understanding of the proteome, making it far easier and
deterministic to prepare reagents and assays for diagnostics
and therapeutics. For example, antibodies of the future can
be constructed for targeted epitopes and even made as
proteoform-specific reagents. Similarly, a drug candidate can
be assessed for returning a specific constellation of proteo-
forms in a pathway back to a healthier state (with far better
knowledge of off-target effects). Drugs and diagnostics can
be devised to target specific protein molecules with a level
of precision that will help drive the century of biology along
the path envisioned by many decades ago. Such hyperfine
control over complex biological systems was part of the
original promise of the genome project; the CB-HPP can
serve as a next bridge to that goal. While drawing from the
HGP experience but acknowledging the strong context-
dependent nature of the proteome, we may indeed see
momentum gathering to develop a comprehensive under-
standing of just what we are at the level of protein
molecules. How can we realize all our goals for the “Century
of Biology” without a transformation in our molecular
comprehension of the proteome?
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Question/Answer Section
Given its scope, the above proposal raises several questions
and critical commentary. Upon sharing the CB-HPP concept
with colleagues, common questions and issues arise, which
are listed below together with responses interwoven through-
out the text that follows.
Comment/Question #1. The notion of cell type is flawed.
Where did the estimate of 4000 cell types come from?
Response #1. When asked, people discuss human cell
types in a range from 230 at the low to 1013 at the upper end.
There is a continuum (particularly in developmental biology
and the brain), but that need not prevent us from taking a
systematic approach to the classification and typing of cells.
A more precise definition of cell type is akin to speciation in
biology. Drawing lines and categorizing across a continuum
has clear value. Such is the same required for cell types to
truly know what the human body is made of. The brain is
particularly diverse when thinking about cell types, some-
thing the Allen Brain Atlas is attempting to define. A recent
study by Tanner and colleagues using unsupervised cluster-
ing settled on a number of 288 cell types in the human
hematopoietic system [11]. Thus cell types can be defined
and serve as a primary index for studies of cell-specific gene
expression.
Question #2. Where did the number of 250,000 proteo-
forms per cell type come from?
Response #2. It is an estimate. There is a paradox at work
here. The combinatorial nature of modifications creates a
huge number of protein proteoforms. This combinatorial
complexity at the whole protein level is made both simpler
and more complicated when proteases are used to digest the
proteome. It is simpler because of the 2n combinatorial
scaling of modifications on whole proteins (e.g., p53 with 15
modifications), yet more complicated with stochastic mea-
surement of peptides and the protein inference problem. To
allow precision definition of a project, the number of
250,000 is a provocative way to specify a level of depth—
it is not a rigorous number and is akin to estimates of gene
count in the human genome that were up to 5-fold off at
early stages of the project. This number allows for the
detection of the top 25 proteoforms for the products from
each of the ~10,000 genes producing protein above a copy
number of 25. This estimate deals with the natural
complexity present by setting a metric of depth. The HGP
also had population variability and a cost versus coverage
problem to balance; ultimately, they chose to limit the
project by both focusing on only healthy samples from a
defined number of individuals. The genome is in fact quite
variable in populations, but a level of depth was set (thanks
in part to the Lander-Waterman Model), and the project
moved into its mapping and technology development stages
with estimates as a guide to frame the project and its cost.
Question #3. Is there a clear endpoint for the CB-HPP?
Response #3. Yes. It is what the community can define
as the analytical target. While the numbers of cell types and
proteoforms are estimates, they serve to conceptually define
sharp edges to a Human Proteome Project.
Issue #4. Judging completeness in mass spectrometry-
based proteomics.
Response #4. Thanks to the great advances in Bottom Up
proteomics combined with RNA-seq, the full extent of gene
expression in a single human cell type is coming into view,
with ~9000–10,000 proteins expressed above a copy number
of ~50 [15, 16]. An expectation of completeness in
proteomics can now be defined. This sets the stage for
‘deep’ determination of the expressed primary structures for
these gene products as whole proteoforms. Polymorphisms
and mutations can be distinguished by comparison of data
from next generation sequencing (NGS) of the same cell
types subjected to next-generation proteomics.
Question #5. Should model organisms be employed for
the CB-HPP?
Response #5. The benchmarking of developmental
technologies is clearly needed. Using a small bacterium
(such as H. influenza, 1.8 Mb, ~1800 ORFs) would serve as
a good testing ground, with graduation to S. cerevisiae
(~4300 expressed genes) similar to the approach taken in the
Human Genome Project. However, single cell types from
primary human samples can be obtained today, allowing
pilot scale projects to commence in the mid-range future.
Question #6. How much does it cost to measure protein
forms right now using top down proteomics?
Response #6. The recent study for high throughput top
down proteomics cost on the order of~$2000 per proteoform
to conduct [14]. Therefore, a 91000× decrease in cost is
required before the $1/proteoform threshold could be
reached. The proteome coverage, particularly for proteins
950 kDa, needs to be expanded through development of new
technology at an accelerated pace.
Question #7. Didn’t either the chromosome-centric or
the biology/disease-driven versions of the HPP already
describe this?
Response #7. There have been some notions of doing
cell-specific work, but a cell-based project as the primary
tenant of the project has not been described widely in the
disease or chromosome-centric versions of the HPP. The use
of Top-Down Mass Spectrometry for interrogation of
primary (or quaternary structure) has also not been
described.
Question #8. Shouldn’t a proteome project also target
protein complexes or organelles?
Response #8. Probably, but given the direct linkage
between crafting a clear vision and project cost—the scope
of work proposed here was crafted in a highly-focused
manner, in part to counteract prior criticisms of the HPP.
The measurement of intact protein complexes, or samples
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providing an organellular context as described in references
[17–19], could be included in an expanded version of a cell-
based project. Others with a clear perspective about how to
sharply define such projects should put forward such
proposals; this would allow funding agencies to select,
which to bring into pilot stage and what the final scope of an
integrated HPP might look like in the years and decades
ahead.
Question #9. Shouldn’t samples from various human
diseases be part of all versions of the Human Proteome
Project?
Response #9. No. The B/D-HPP project is open-ended
because disease biology is included in its articulation. Such
was clearly not the case with the Human Genome Project,
and the cell based-HPP follows its example closely. The
Human Genome Project sequenced the genomes of five
people (private effort) or 22 people (public effort), all
deemed ‘healthy.’ Now that technologies for NGS of
DNA/RNA are available, they are readily applied to samples
from patients suffering all types of human disease (e.g., the
1000 Cancer Genomes project). However, including such
samples early in a project requiring next-generation tech-
nologies for proteomics makes it very difficult to define a
focused effort with precision.
Question #10. What might be some intermediate mile-
stones besides the final deliverable of the CB-HPP?
Response #10. The cell types in the human hematopoetic
system provide a clear focal point, not requiring the creation of
single cell suspensions from human tissue. A recent study
concluded that there were ~288 cell types discovered in a
systematic approach using mass cytometry [11]. The final
number is less important than realizing that a number can be
found, even when there exists a continuum of cells undergoing
differentiation from bone marrow to say, for example mature
B-cells. This would serve as a proving ground for the project,
with mononuclear cell types readily accessible from human
blood. Determination of the proteomes from these cell types
could lead to early disease-driven projects to commence in
parallel with the CB-HPP focused on normal biology.
Issue #11. Protein quantification in the CB-HPP.
Response #11. The quantification of proteoforms is clearly
part of the project. For determining a “parts list” for all types of
cells, the section on histones above provides hints regarding the
ability of MS to determine the relative abundance of expressed
proteoforms. Absolute abundance is a separate goal, with that
requiring significant technology development that would
synergize nicely with the C-HPP. Quantification of proteins
in a catalogue will be enabling, with the technology to
accomplish this clearly of diagnostic value when analyzing
samples from across the spectrum of human disease.
Question #12. Is the proteome is too dynamic to draw a
useful analogy to the human genome project?
Response #12. No. The cellular and molecular variability
of ‘normal’ at the protein level is higher than that for DNA,
but this variation is not so high that it cannot be tracked in
populations by introducing a type “temperature factor” for
PTMs present on proteoforms (once they can be measured
reasonably well). There will be protein differences that are
stable and we should launch a project to define what these
are at the cellular level.
Issue #13. The proteome is too complex to describe a
focused, transformative project.
Response #13. It is true that we do not know that the
Human Proteome Project (in any form) will ever become the
“singularity” akin to the Human Genome Project. We seek a
core focus to serve as a compelling stimulus for accelerated
development of disruptive proteomics technology to im-
prove the human condition.
Question #14. How would the outcomes of the CB-HPP
be used by the research community? In contrast to the
genome sequence, the utility for biological experimentation
of a proteome reference map is not so easily apparent.
Response #14. The four main outcomes of the CB-HPP
would be:
 A clear taxonomy of human cell types and their natural
variation
 Technologies and reagents to define, sort, and in-situ
image cell types
 Technologies for next-generation proteomics
 A reference list of proteoforms within all cell types
Like the genome project, one outcome would be enabling
new technologies and knowledge bases that could be used in
all areas of disease research and biology. Another expecta-
tion is that the statistical power of top down proteomics will
allow stronger statistical correlations to complex phenotypes
in complex populations to prevent suffering from late stage
disease. Defining normal cell types and their proteoforms
would then allow us define disease far more precisely, and
detect it in its earliest stages more reliably and with greater
return on investment. Beyond the arguments made at the end
of the main text, the CB-HPP would allow us to better
understand the post-translational language operative within
our cells. It was partly at the level of whole proteins that
evolutionary pressure has been applied, thus expanding our
biology far beyond that possible with ‘only’ 20,300 genes
[22]. Therefore, measuring proteoforms whole and quantita-
tively on a large, transformative scale has a great potential to
transform 21st century biology by providing a thorough
“Bottom Up” knowledge of protein molecules present in
healthy and diseased cells.
Issue #15. The CB-HPP is a structurally based project.
Response #15. So too was the genome project;
population and temporal dynamics are proceeding now.
The HGP was based on the primary sequence (structure)
of DNA. Focusing on the primary structure of proteins
allows articulation of a highly defined project. Focusing
on quaternary structure as a separate articulation would
add an important aspect with its associated costs. A
project based on function is very difficult to frame with
precision.
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Issue #16. It is hardly foreseeable that proteomics could
be done on the scale proposed.
Response #16. It was hardly foreseeable that even a
single human genome could be sequenced in 1986.
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